Quick Answer
BioRestorative Therapies, Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025.
BioRestorative Therapies, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.58 | -36.2% |
| 2024 | -$1.16 | +53.0% |
| 2023 | -$2.47 | +51.7% |
| 2022 | -$5.11 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | -153.8% | -10.0% |
| June 30, 2025 | -$0.30 | +40.0% | +53.1% |
| March 31, 2025 | -$0.64 | -93.9% | -392.3% |
| September 30, 2024 | -$0.13 | -133.3% | +74.0% |
| June 30, 2024 | -$0.50 | +66.0% | -51.5% |
| March 31, 2024 | -$0.33 | +82.9% | -184.6% |
| September 30, 2023 | $0.39 | +130.5% | +126.5% |
| June 30, 2023 | -$1.47 | -14.8% | +23.8% |
- BioRestorative Therapies, Inc. showed a decrease of -36.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, BioRestorative Therapies, Inc.’s diluted eps has grown by 69.1% (from $5.11 per share (loss) to $1.58 per share (loss)).
- The most recent figure is from BioRestorative Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: